Adocia: Activity and results for the first half of 2013

barbara.lempert

Intensification of R&D ahead of the launch of three clinical trials for insulin projects, starting in the second of

Net result of EUR -4.6 million as a result of step-up in R&D spending

Sound financial position: EUR 22.8 million in cash

Lyon, France, September 5, 2013 – (NYSE Euronext Paris: FR0011184241 – ADOC), a biotechnology company specializing in the development of ‘best-in-class’ medicines from already approved therapeutic proteins, announces today its financial for the six months of 2013.
 
IFRS half year financial results for the period from January 1 to June 30, 2013 have been submitted for a limited review by our financial auditors and validated by our board meeting held on September 4, 2013 and authorized for publication. The 2013 half year report is available on Adocia’s website, in French only, Investors/Regulated Information/Financial report (http://www.adocia.com/Investors,en,52.html).
 
Significant events of the first half of 2013:
•    Intensification of research activity in order to gather clinical data for the three planned clinical trials on type I diabetes patients. These trials are expected to take place during the second half of 2013 for the insulin combo, the fast-acting human insulin Hinsbet(R)  and the ultra fast-acting insulin analog projects.
•    A strengthened patent portfolio, with the approval of three new patents in the USA. These include one major patent covering BioChaperone(R) projects in clinical development and the filing of two new patents covering innovations in the field of insulin.
•    A positive scientific opinion from the European Medicines Agency (EMA), confirming only one European phase III clinical trial for the diabetic foot ulcer treatment would be required in order to receive marketing authorization. In India, reorganization in the…Read more

Pharmalive – The Pulse of the Pharmaceutical Industry

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS